Voyager Therapeutics (VYGR) AI Stock Analysis

• Market Cap: $257.93M
• Dividend Yield: N/A
• Average Volume (3M): 780.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.36
• Revenue Growth: -70.38%
• EPS Growth: -683.06%
• Country: US
• Employees: 172
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 55,468,807
• 10 Day Avg. Volume: 615,896
• 30 Day Avg. Volume: 780,688
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.03
• Enterprise Value/Revenue: 0.17
• Enterprise Value/Gross Profit: 0.17
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: $16.14
• Price Target Upside: 246.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 53 Neutral
• Price Target: $5.00 ▲(7.30% Upside)

Voyager Therapeutics' stock score is primarily influenced by its financial performance challenges, including negative profit margins and unstable cash flows. While technical analysis indicates bullish momentum, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation, resulting in a moderate overall score.

Positive Factors

Proprietary AAV Platform

Voyager's proprietary AAV platform provides a competitive advantage in delivering gene therapies, crucial for addressing neurological diseases, which supports long-term growth potential.

Partnerships and Collaborations

Strong partnerships with major pharmaceutical companies enhance Voyager's pipeline development and market reach, providing a sustainable revenue model and potential for future growth.

Manageable Leverage

A low debt-to-equity ratio indicates manageable leverage, providing Voyager with financial flexibility to invest in R&D and strategic initiatives, supporting long-term stability.

Negative Factors

Revenue Volatility

The substantial decline in revenue growth reflects challenges in achieving consistent revenue streams, which can hinder long-term financial stability and growth prospects.

Negative Profit Margins

Ongoing negative profit margins indicate operational challenges, which could impact Voyager's ability to achieve profitability and sustain its operations in the long term.

Fluctuating Cash Flow

Instability in cash flow management can limit Voyager's capacity to fund research and development, impacting its ability to innovate and maintain a competitive edge.

Voyager Therapeutics Business Overview & Revenue Model

Company Description

Voyager Therapeutics (VYGR) is a biotechnology company focused on developing innovative gene therapies for serious neurological diseases. The company specializes in leveraging its proprietary adeno-associated viral (AAV) vector platform to deliver therapeutic genes directly to the central nervous system. Voyager's core areas of focus include conditions such as Parkinson's disease, Huntington's disease, and other neurodegenerative disorders, with a pipeline that includes both preclinical and clinical-stage programs aimed at addressing significant unmet medical needs.

How the Company Makes Money

Voyager Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments tied to the achievement of specific development goals, and royalties on product sales. Additionally, the company may receive funding from grants or government programs aimed at advancing research in gene therapy. Their revenue model is heavily dependent on the successful progression of their clinical trials and the commercialization of their therapies, as well as maintaining strong relationships with industry partners to enhance their product pipeline and potential market reach.

Voyager Therapeutics Financial Statement Overview

Summary

Voyager Therapeutics is facing financial challenges with declining revenues and profitability. The balance sheet shows a stable equity position, but increasing leverage and negative cash flows are concerns. The company needs to address operational inefficiencies to improve financial health.

Income Statement

Voyager Therapeutics has experienced significant revenue volatility, with a notable decline in revenue from 2023 to TTM. The gross profit margin has decreased, and the company is currently operating at a net loss, impacting net profit margins negatively. The EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, suggesting financial stability. However, the debt-to-equity ratio has increased slightly, indicating a rise in leverage. Return on equity is negative due to net losses, which is a concern for profitability.

Cash Flow

Operating cash flow is negative, reflecting cash burn, but the company has managed to maintain a positive free cash flow growth rate in TTM. The operating cash flow to net income ratio is unfavorable due to negative net income, indicating cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	42.58M	80.00M	250.01M	40.91M	37.41M	171.13M
Gross Profit	42.58M	80.00M	245.57M	34.72M	-36.37M	62.38M
EBITDA	-119.17M	-78.56M	126.45M	-44.65M	-68.45M	31.20M
Net Income	-107.93M	-65.00M	132.33M	-46.41M	-66.03M	36.74M
Balance Sheet
Total Assets	322.10M	393.05M	351.28M	159.36M	193.85M	261.58M
Cash, Cash Equivalents and Short-Term Investments	215.59M	266.68M	230.88M	118.85M	132.54M	181.14M
Total Debt	40.20M	43.73M	20.29M	23.13M	44.18M	47.61M
Total Liabilities	78.16M	93.29M	114.96M	100.34M	98.80M	107.26M
Stockholders Equity	243.94M	299.76M	236.32M	59.02M	95.06M	154.32M
Cash Flow
Free Cash Flow	-115.83M	-18.83M	74.66M	-15.00M	-55.13M	-108.81M
Operating Cash Flow	-113.65M	-15.31M	77.92M	-12.51M	-53.52M	-96.72M
Investing Cash Flow	80.28M	-94.86M	-141.64M	-7.34M	65.91M	113.00M
Financing Cash Flow	1.18M	114.02M	33.65M	1.11M	612.00K	3.16M

Voyager Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYGR, the sentiment is Neutral. The current price of 4.66 is below the 20-day moving average (MA) of 4.91, above the 50-day MA of 4.35, and above the 200-day MA of 3.87, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 48.86 is Neutral, neither overbought nor oversold. The STOCH value of 18.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VYGR.

Voyager Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLN	―	$307.02M	―	―	―	―	―
VYGR	―	$257.93M	―	-37.26%	―	-70.38%	-683.06%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RNAC	―	$216.34M	-0.16	―	―	―	―
TNYA	―	$270.54M	-1.73	-85.21%	―	―	38.94%
KYTX	―	$286.72M	―	-61.29%	―	―	-39.69%
GALT	―	$329.27M	-7.99	―	―	―	17.80%

Voyager Therapeutics Corporate Events

Voyager Therapeutics Joins Citi’s Biopharma Conference 2025

Voyager Therapeutics announced its participation in Citi’s 2025 Biopharma Back to School Conference, highlighting its strategic advancements in neurotherapeutics. The company aims to optimize the delivery of therapeutics to the central nervous system through its innovative platforms, and anticipates significant clinical milestones in the coming years. This announcement underscores Voyager’s commitment to advancing its pipeline and strengthening its industry position, supported by substantial non-dilutive funding and collaborations.

The most recent analyst rating on (VYGR) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Voyager Therapeutics stock, see the VYGR Stock Forecast page.

Voyager Therapeutics Extends Cash Runway to 2028

Voyager Therapeutics, Inc. is a biotechnology company focused on using genetic approaches to treat neurological diseases, with a notable presence in the Alzheimer’s disease research sector. In its second quarter 2025 earnings report, Voyager Therapeutics highlighted its extended cash runway into 2028, the addition of a new APOE program to its Alzheimer’s disease pipeline, and the potential for significant milestone payments from its partnered programs. Key financial metrics showed a decrease in collaboration revenue to $5.2 million from $29.6 million year-over-year, while research and development expenses slightly decreased, and the company reported a net loss of $33.4 million for the quarter. Despite the financial challenges, Voyager’s strategic focus remains on advancing its clinical programs, with expectations to have four programs in the clinic by next year. Looking ahead, Voyager Therapeutics is positioned to reach multiple clinical milestones, supported by its strong cash position and strategic partnerships, as it continues to pursue advancements in neurotherapeutics.